Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis.
about
Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancerAn updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients.[Bevacizumab combined with chemotherapy for advanced non-small cell lung cancer: a meta-analysis].Eligibility for bevacizumab as an independent prognostic factor for patients with advanced non-squamous non-small cell lung cancer: a retrospective cohort study.Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Efficacy and safety profile of combining vandetanib with chemotherapy in patients with advanced non-small cell lung cancer: a meta-analysis.The non-coding RNAs of the H19-IGF2 imprinted loci: a focus on biological roles and therapeutic potential in Lung Cancer.Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.The efficacy of combining antiangiogenic agents with chemotherapy for patients with advanced non-small cell lung cancer who failed first-line chemotherapy: a systematic review and meta-analysisBuilding better monoclonal antibody-based therapeutics.Customised, Individualised Treatment of Metastatic Non-Small-Cell Lung Carcinoma (NSCLC)Comparison of bevacizumab plus chemotherapy with chemotherapy alone in advanced non-small-lung cancer patientsGefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapyPractical management of NSCLC patients with long-term bevacizumab treatment: a report of four cases.Risk profile of bevacizumab in patients with non-small cell lung cancer: a meta-analysis of randomized controlled trials.Issues surrounding clinical trial endpoints in solid malignancies with a focus on metastatic non-small cell lung cancer.Clinical meta-analyses of targeted therapies in adenocarcinoma.Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspective.Prognostic and predictive biomarkers in lung cancer. A review.Resistance to anti-angiogenic agents: a brief review of mechanisms and consequences.Detailed assessment of microvasculature markers in non-small cell lung cancer reveals potentially clinically relevant characteristics.Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials.Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group.Bevacizumab in the treatment of NSCLC: patient selection and perspectives.Quantitative analysis of VEGF-C mRNA of extrahepatic cholangiocarcinoma with real-time PCR using samples obtained during endoscopic retrograde cholangiopancreatography.Anti-angiogenic therapy in nonsquamous non-small cell lung cancer (NSCLC) with tyrosine kinase inhibition (TKI) that targets the VEGF receptor (VEGFR): perspective on phase III clinical trials.The efficacy and safety of paclitaxel and carboplatin with versus without bevacizumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis.Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P2860
Q27011293-A8E4B366-0268-4FC7-BCA3-6916118AB85FQ31152878-3CEEBEEE-DB61-462D-87E3-B2274C911750Q34593475-EC08E2F5-D098-42FE-B6AA-F79DB4F2AA74Q34651916-FF8F60A0-6F0C-45DF-99B3-17B66DB029FCQ34663877-99E8ABB5-B870-4AD3-AB4D-29A21720D07FQ34826532-9A39A6BC-8F35-4BE1-B77F-AF9B529B20B8Q35425128-76DFD461-8F67-442A-A611-06F3121BA7F3Q35545472-DD0E21DF-9C1B-488D-BE46-CF24DE26A2D2Q35649624-790FC7F6-3863-4BAD-9CA0-A21B45C85258Q35817552-F24A14AD-A988-4375-870E-A84876A342E4Q36996220-518CAC39-FA29-46DA-AE33-C0E35F756957Q37152528-A8853CAE-04F8-4D71-B745-88F78C75985BQ37566619-33A6CBC1-3F5B-4C7F-8500-0B0BBBBB64EBQ37566624-27FE0494-5862-4007-865A-0531DFA1EE2FQ37956392-02412F72-24E1-4D79-90D8-0A6F37A53B80Q38026294-ABE14BC8-87B8-4B3C-A4BC-587996F39C0FQ38077126-F94E0F13-44B3-4216-88A9-9EC9DFA4714AQ38153445-66122835-B2C3-479A-850F-25F23B4DB979Q38178187-CD857830-0E0F-4BAB-9306-359C92E912D8Q38390060-A0BEDE77-1F55-44D5-8E70-C09B2684604FQ41099763-01DE8C22-F69D-4F34-8438-AEC784C57E00Q44029291-3C2413C7-4A80-4155-B104-8083941FA8EAQ46948139-9EE53706-CE8B-4F35-B6FA-DF163FD8D1F5Q47168527-B06342FE-22A5-413C-9663-0319F825291FQ50950470-F5BE1710-A4BE-4B1C-A9C0-D614CE0DDB4AQ52722352-ACA039F4-62AA-4B28-B0F6-6B551B17E91EQ55083555-5EF22C58-3024-43B5-8354-549F9BBB08C9Q59274003-866E28F7-7E42-4102-88C0-68611FF1B6FF
P2860
Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Addition of bevacizumab to che ...... atic review and meta-analysis.
@ast
Addition of bevacizumab to che ...... atic review and meta-analysis.
@en
type
label
Addition of bevacizumab to che ...... atic review and meta-analysis.
@ast
Addition of bevacizumab to che ...... atic review and meta-analysis.
@en
prefLabel
Addition of bevacizumab to che ...... atic review and meta-analysis.
@ast
Addition of bevacizumab to che ...... atic review and meta-analysis.
@en
P2093
P2860
P31
P921
P1433
P1476
Addition of bevacizumab to che ...... atic review and meta-analysis.
@en
P2093
André Bacellar Costa Lima
André Deeke Sasse
Ligia T Macedo
P2860
P304
P356
10.1371/JOURNAL.PONE.0022681
P407
P5008
P577
2011-08-02T00:00:00Z